New approaches for empiric therapy in Gram-positive sepsis

Minerva Anestesiologica

Volumn 77, Issue 8, 2011, Pages 821-827

  Bassetti, M ^a   Ginocchio, F ^a   Giacobbe, D R ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Blood circulation; Gram positive bacterial infections; Intensive care units

Indexed keywords

DAPTOMYCIN; LINEZOLID; TIGECYCLINE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BLOODSTREAM INFECTION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; EMPIRICAL RESEARCH; ENTEROCOCCAL INFECTION; GRAM POSITIVE INFECTION; HUMAN; INCIDENCE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; SEPSIS; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE; SEPSIS;

EID: 79960952287     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Chen YY, Wang FD, Liu CY, Chou P. Incidence rate and variable cost of nosocomial infections in different types of intensive care units. Infect Control Hosp Epidemiol 2009;30:39-46.
2. Durando P, Icardi G, Ansaldi F, Crimi P, Sticchi C, Compagnino F et al. Surveillance of hospital-acquired infections in Liguria, Italy: results from a regional prevalence study in adult and paediatric acute-care hospitals. J Hosp Infect 2009;71:81-7.
3. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39;309-17.
4. R. Introduction: treatment of Gram-positive infections. J Antimicrob Chemother 2003;51(Suppl 2):ii5-7.
5. European Antimicrobial Surveillance System. EARSS Annual Report 2008.
6. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteraemia on patients outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005;26:166-74.
7. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398-402.
8. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166:2138-44.
9. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004;38:1700-5.
10. Moise PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007;51:2582-6.
11. Rodríguez-Baño J, Millán AB, Domínguez MA, Borraz C, González MP, Almirante B et al. Impact of inappropriate empirical therapy for sepsis due to health care-associated methicillin-resistant Staphylococcus aureus. J Infect 2009;58:131-7.
12. Khatib R, Saeed S, Sharma M, Riederer K, Fakih MG, Johnson LB. Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2006;25:181-5.
13. Freid VM, Prager K et al. Health, United States, 2003. Hyattsville, MA: National Center for Health Statistics; 2003.
14. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B; CUB-Réa Network. Current epidemiology of septic shock. Am J Respir Crit Care Med 2003;168;165-72.
15. EPISEPSIS Study Group. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 2004;30:580-8.
16. Pittet D, Wenzel R. Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths. Arch Intern Med 1995;155:1177-84.
17. Warren DK, Zack JE, Elward AM, Cox MJ, Fraser VJ. Nosocomial primary bloodstream infections in intensive care unit patients in a nonteaching community medical centre: a 21-month prospective study. Clin Infect Dis 2001;33:1329-35.
18. Smith TL, Jarvis WR. Antimicrobial resistance in Staphylococcus aureus. Microbes infect 1999;1:795-805.
19. Diekema DJ, Pfaller MA, Schmitz FJ, Smaveysky J, Bell J, Jones RN et al. SENTRY Participants Group. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32:S114-S32.
20. Doern GV, Jones RN, Pfaller MA, Erwin M, Ramirez- Rhonda C. Multicenter evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents in Puerto Rico. The Puerto Rico Antimicrobial Resistance Study Group. Diagn Microbol Infect Dis 1998;30:113-9.
21. W yllie DH, Crook DW, Peto TE. Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997-2003: cohort study. BMJ 2006;332:281-4.
22. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, archmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003;36:53-9.
23. Barber M. Methicillin-resistant staphylococci. J Clin Pathol 1961;14:385-93.
24. P anlilio AL, Culver DH, Gaynes RP, Banerjee S, Henderson TS, Tolson JS et al. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991. Infect Control Hosp Epidemiol 1992;13:582-6.
25. NNIS System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003;31:481-98.
26. Nicoletti G, Schito G, Fadda G, Boros S, Nicolosi D, Marchese A et al. Bacterial isolates from severe infections and their antibiotic susceptibility patterns in Italy: a nationwide study in the hospital setting. J Chemother 2006;18:589-602.
27. Ena J, Dick RW, Jones RN, Wenzel RP. The epidemiology of intravenous vancomycin usage in a university hospital: a 10-year study. JAMA 1993;269:598-602.
28. Soriano A, Marco F, Martìnez JA, Pisos E. Almela M, Dimora VP et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillinresistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193-200.
29. Campanile F, Bongiorno D, Borbone S, Stefani S. Hospital- associated methicillin-resistant Staphylococcus aureus (HA-MRSA) in Italy. Ann Clin Microbiol Antimicrob 2009;24:8-22.
30. Vancomycin-intermediate Staphylococcus aureus (VISA), and Vancomycin-resistant Staphylococcus aureus (VRSA) 2007 Case Definition. CSTE Position Statement Number: 09-ID-58, 09-ID-59. [Last accessed on 2010 July 30, cited 2011 March 29]. Available at: http://www.cdc.gov/ncphi/disss/nndss/casedef/vancomycincurrent.htm
31. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration- time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009;49:507-14.
32. Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996;23:1234-9.
33. DiazGranados CA, Zimmer AM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 2005;41:327-33.
34. Champney WS, Miller M. Linezolid is a specific inhibitor of 50S ribosomal subunit formation in staphylococcus aureus cells. Curr Microbiol 2002;44:350-6.
35. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002;34:1481-90.
36. Ben Mansour EH, Jacob E, Monchi M, Ledoux D, Canivet JL, De Mol P et al. Occurrence of MRSA endocarditis during linezolid treatment. Eur J Clin Microbiol Infect Dis 2003;22:372-3.
37. Sperber SJ, Levine JF, Gross PA. Persistent MRSA bacteremia in a patient with low linezolid levels. Clin Infect Dis 2003;36:675-6.
38. Wilcox MH, Tack KJ, Bouza E, Herr DL, Ruf BR, Iizerman MM et al. Complicated skin and skin structure infections and catheter related bloodstream infections: noninferiority of Linezolid in a phase 3 study. Clin Infect Dis 2009;48:203-12.
39. Lustberg ME, Schlesinger LS, Mangino JE. Concerns about "Complicated skin and skin-structure infections and catheter- related bloodstream infections: noninferiority of linezolid in a phase 3 study". Clin Infect Dis 2009;49:313,author reply 314-5.
40. Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteremia: pooled analysis of randomized studies. J Antimicrob Chemother 2005;56:923-9.
41. Conte JE Jr, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002;46:1475-80.
42. Wong A, Reddy SP, Smyth DS, Aguero-Rosenfeld ME, Sakoulas G, Robinson DA. Polyphyletic emergence of linezolid- resistant staphylococci in the United States. Antimicrob Agents Chemother 2010;54:742-8.
43. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycinresistant Enterococcus fecium resistant to linezolid. Lancet 2001;357:1179.
44. Sinclair A, Arnold C, Woodford N. Rapid detection and estimation by pyrosequencing of 23S rRNA genes with a single nucleotide polymorphism conferring linezolid resistance in enterococci. Antimicrob Agents Chemother 2003;47:3620-2.
45. Bassetti M, Farrel PA, Callan DA, Topal JE, Dembry LM. Emergence of linezolid-resistant Enterococcus faecium during treatment of enterococcal infections. Int J Antimicrob Agents 2003;21:593-4.
46. Peterson LR. A review of tigecycline--the first glycylcycline. Int J Antimicrob Agents 2008;32(Suppl 4):S215-22.
47. Devasahayam G, Scheld WM, Hoffman PS. Newer antibacterial drugs for a new century. Expert Opin Investig Drugs 2010;19:215-34.
48. Florescu I, Beuran M, Dimov R, Razbadauskas A, Bochan N, Fichey G et al. Efficacy and safety of tygecicline compared with vancomycin or linezolid for treatment of serious infections with methicillin-restistant Staphylococcus aureus or vancomycin-resistant enterococci: a phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008;62:i17-i28.
49. Hawkey PM. Pre-clinical experience with daptomycin. J Antimicrob Chemother 2008;62:iii7-iii14.
50. Cubist Pharmaceuticals. Cubicin (daptomycin for injection) prescribing information. Lexington, MA: Cubist Pharmaceutical, 2006.
51. Barry AL, Fuchs PC, Brown SD. In vitro activities of daptomycin against 2 789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001;45:1919-22.
52. Streit JM, Jones RN, Sader HS. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. J Antimicrob Chemother 2004;53:669-74.
53. LaPlante KL, Woodmansee S. Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis. Antimicrob Agents Chemother 2009;53:3880-6.
54. Smith K, Perez A, Ramage G, Gemmell CG, Lang S. Comparison of biofilm-associated cell survival following in vitro exposure of methicillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin. Int J Antimicrob Agents 2009;33:374-8.
55. Arbeit RD, Maki D, Tally FP, Campanaro E, Einstein BI. The safety and efficay of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38:1673-81.
56. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653-65.
57. Boucher HW, Sakoulas G. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 2007;45:601-60.
58. Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 2006;44:655-6.
59. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006;50:3245-9.
60. Cunha BA, Eisenstein LE, Hamid NS. Pacemaker- induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: cure with prolonged/high-dose daptomycin without toxicity. Heart Lung 2006;35:207-11.
61. Cunha BA, Krol V, Kodali V. Methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE) in a patient with Job' syndrome (hyperimmunoglobulin E syndrome) successfully treated with linezolid and high-dose daptomycin. Heart Lung 2008;37:72-5.
62. Katz DE, Lindfield KC, Steenbergen JN, Benziger DP, Blackerby KJ, Knapp AG et al. A pilot study of high-d with complicated skin and skin structure infections caused by gram- positive bacteria. Int J Clin Pract 2008;62:1455-64.
63. Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC. Safety and clinical outcomes when utilizing highdose (=8 mg/kg) daptomycin therapy. Ann Pharmacother 2009;43:1211-9.
64. Figueroa DA, Mangini E, Amodio-Groton M, Vardianos B, Melchert A, Fana C et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009;49:177-80.
65. Bassetti M, Nicco E, Ginocchio F, Ansaldi F, de Florentiis D, Viscoli C. High-dose daptomycin in documented Staphylococcus aureus infections. Int J Antimicrob Agents 2010 [Epub ahead of print].
66. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005;191:2149-52.